CEO Jonathan Cohen Discloses 16.8% Stake in 20/20 Biolabs, Including Recent Option Grants
Summary
CEO Jonathan Cohen has filed an initial Schedule 13D, disclosing a beneficial ownership of 16.8% of 20/20 Biolabs, Inc.'s common stock, primarily through shares acquired for services and vested stock options.
Key Events
-
CEO Discloses Significant Stake
Jonathan Cohen, CEO of 20/20 Biolabs, Inc., has filed an initial Schedule 13D, reporting beneficial ownership of 1,833,750 shares, representing 16.8% of the company's outstanding common stock.
-
Shares Acquired for Services and Options
The reported stake includes 1,366,400 shares received for services in 2000 and 467,350 shares exercisable within 60 days from vested stock options, with the latest option grant on March 3, 2026.
-
No Immediate Plans for Corporate Changes
The filing states that the Reporting Person has no current plans or proposals that would result in major corporate events or changes to the company's structure or business.
Analysis
This initial Schedule 13D filing reveals that CEO Jonathan Cohen holds a substantial 16.8% stake in 20/20 Biolabs, Inc. Such a significant ownership percentage by a chief executive officer typically signals strong alignment with shareholder interests and confidence in the company's long-term prospects. The stake includes shares received for services and a substantial portion of vested stock options, with the most recent option grant occurring on March 3, 2026. While the filing does not indicate any immediate plans for corporate changes, the disclosure of such a concentrated insider holding is a key indicator for investors.
At the time of this filing, AIDX was trading at $2.91 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $13.8M. The 52-week trading range was $2.51 to $50.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.